ARCHIVES

Revlimid Extends Time To Progression Compared To Placebo In Phase III Trial

This article is from The Cancer Letter archive.

Vol. 32 No. 12 | December 25, 2009

Download PDF Visit The Full Archive

Related Articles

DeVita: No Decision Yet On FCRF Award

July 17, 1987

Tamoxifin Benefits Outweigh Risks, NSABP Study Finds

March 23, 1994

Two cancer center directors named: Michael Kastan at St. Jude, James Willson at Harold Simmons.

December 10, 2004

In Brief Yale Cancer Center Begins Reorganization, Names New Deputy Director, Prevention Chief

January 6, 1995

Academic Oncologists Reluctant To Give ESAs In Adjuvant Breast Cancer Setting.

December 7, 2007

Tobacco Council Announces 11 New Grant Awards

January 24, 1975